nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.02.2012 | Review Article

Radiopharmaceutical development of radiolabelled peptides

verfasst von: Melpomeni Fani, Helmut R. Maecke

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Receptor targeting with radiolabelled peptides has become very important in nuclear medicine and oncology in the past few years. The overexpression of many peptide receptors in numerous cancers, compared to their relatively low density in physiological organs, represents the molecular basis for in vivo imaging and targeted radionuclide therapy with radiolabelled peptide-based probes. The prototypes are analogs of somatostatin which are routinely used in the clinic. More recent developments include somatostatin analogs with a broader receptor subtype profile or with antagonistic properties. Many other peptide families such as bombesin, cholecystokinin/gastrin, glucagon-like peptide-1 (GLP-1)/exendin, arginine-glycine-aspartic acid (RGD) etc. have been explored during the last few years and quite a number of potential radiolabelled probes have been derived from them. On the other hand, a variety of strategies and optimized protocols for efficient labelling of peptides with clinically relevant radionuclides such as ^99mTc, M³⁺ radiometals (¹¹¹In, ^86/90Y, ¹⁷⁷Lu, ^67/68Ga), ^64/67Cu, ¹⁸F or radioisotopes of iodine have been developed. The labelling approaches include direct labelling, the use of bifunctional chelators or prosthetic groups. The choice of the labelling approach is driven by the nature and the chemical properties of the radionuclide. Additionally, chemical strategies, including modification of the amino acid sequence and introduction of linkers/spacers with different characteristics, have been explored for the improvement of the overall performance of the radiopeptides, e.g. metabolic stability and pharmacokinetics. Herein, we discuss the development of peptides as radiopharmaceuticals starting from the choice of the labelling method and the conditions to the design and optimization of the peptide probe, as well as some recent developments, focusing on a selected list of peptide families, including somatostatin, bombesin, cholecystokinin/gastrin, GLP-1/exendin and RGD.

Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1:242–4.PubMedCrossRef

Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389–427.PubMedCrossRef

Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:247–58.PubMedCrossRef

Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, Reubi JC, et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem 2005;48:100–10.PubMedCrossRef

Abiraj K, Mansi R, Tamma ML, Forrer F, Cescato R, Reubi JC, et al. Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours. Chemistry 2010;16:2115–24.PubMedCrossRef

Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, et al. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med 2000;27:628–37.PubMedCrossRef

Ferro-Flores G, Arteaga de Murphy C, Rodriguez-Cortés J, Pedraza-López M, Ramírez-Iglesias MT. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun 2006;27:371–6.PubMedCrossRef

Shi J, Jia B, Liu Z, Yang Z, Yu Z, Chen K, et al. 99mTc-labeled bombesin(7–14)NH2 with favorable properties for SPECT imaging of colon cancer. Bioconjug Chem 2008;19:1170–8.PubMedCrossRef

von Guggenberg E, Behe M, Behr TM, Saurer M, Seppi T, Decristoforo C. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin. Bioconjug Chem 2004;15:864–71.CrossRef

10.

Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318–25.PubMedCrossRef

11.

Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, et al. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 2010;51:1059–67.PubMedCrossRef

12.

Alberto R. The chemistry of technetium–water complexes within the manganese triad: challenges and perspectives. Eur J Inorg Chem 2009:21–31.

13.

Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010;110:2858–902.PubMedCrossRef

14.

Fani M, Good S, Maecke HR. Radiometals (non-Tc, non-Re) and bifunctional labeling chemistry. In: Vértes A, Nagy S, Klencsár Z, Lovas RG, Rösch F, editors. Handbook of nuclear chemistry. Heidelberg: Springer; 2011. p. 2143–78.CrossRef

15.

Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, et al. [68Ga]NODAGA-RGD for imaging alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2011;38:1303–12.PubMedCrossRef

16.

Wadas TJ, Anderson CJ. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc 2006;1:3062–8.PubMedCrossRef

17.

Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Validation of a novel CHX-A″ derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A″-octreotide. J Med Chem 2006;49:4297–304.PubMedCrossRef

18.

Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917–20.PubMedCrossRef

19.

Velikyan I, Beyer GJ, Långström B. Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. Bioconjug Chem 2004;15:554–60.PubMedCrossRef

20.

Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Behe M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;5:1974–81.CrossRef

21.

Eisenwiener KP, Powell P, Mäcke HR. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg Med Chem Lett 2000;10:2133–5.PubMedCrossRef

22.

Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002;13:530–41.PubMedCrossRef

23.

Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009;50:1168–77.PubMedCrossRef

24.

Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, et al. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 2004;10:8674–82.PubMedCrossRef

25.

Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha(nu)beta(3) integrin expression and facile radiosynthesis. J Nucl Med 2011;52:1276–84.PubMedCrossRef

26.

Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, et al. [64Cu-NOTA-8-Aoc-BBN(7–14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A 2007;104:12462–7.PubMedCrossRef

27.

Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med 2011;52:1110–8.PubMedCrossRef

28.

Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, et al. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med 2011;52:470–7.PubMedCrossRef

29.

Cai H, Fissekis J, Conti PS. Synthesis of a novel bifunctional chelator AmBaSar based on sarcophagine for peptide conjugation and (64)Cu radiolabelling. Dalton Trans 2009;27:5395–400.PubMedCrossRef

30.

Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999;40:1029–44.PubMed

31.

Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 1999;40:1061–71.PubMed

32.

Gotthardt M, Fischer M, Naeher I, Holz JB, Jungclas H, Fritsch HW, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 2002;29:597–606.PubMedCrossRef

33.

Garg S, Garg PK, Zalutsky MR. N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination. Bioconjug Chem 1991;2:50–6.PubMedCrossRef

34.

Vaidyanathan G, Zalutsky MR. Synthesis of N-succinimidyl 4-[18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nat Protoc 2006;1:1655–61.PubMedCrossRef

35.

Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006;47:492–501.PubMed

36.

Schottelius M, Poethko T, Herz M, Reubi JC, Kessler H, Schwaiger M, et al. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004;10:3593–606.PubMedCrossRef

37.

Höhne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, et al. Synthesis, 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem 2008;19:1871–9.PubMedCrossRef

38.

Mu L, Honer M, Becaud J, Martic M, Schubiger PA, Ametamey SM, et al. In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem 2010;21:1864–71.PubMedCrossRef

39.

Hultsch C, Schottelius M, Auernheimer J, Alke A, Wester HJ. (18)F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK). Eur J Nucl Med Mol Imaging 2009;36:1469–74.PubMedCrossRef

40.

Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage EN, et al. PET of insulinoma using (18)F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm 2011;8:1775–82.PubMedCrossRef

41.

Wuest F, Berndt M, Bergmann R, van den Hoff J, Pietzsch J. Synthesis and application of [18F]FDG-maleimidehexyloxime ([18F]FDG-MHO): a [18F]FDG-based prosthetic group for the chemoselective 18F-labeling of peptides and proteins. Bioconjug Chem 2008;19:1202–10.PubMedCrossRef

42.

Hausner SH, Marik J, Gagnon MK, Sutcliffe JL. In vivo positron emission tomography (PET) imaging with an alphavbeta6 specific peptide radiolabeled using 18F-“click” chemistry: evaluation and comparison with the corresponding 4-[18F]fluorobenzoyl- and 2-[18F]fluoropropionyl-peptides. J Med Chem 2008;51:5901–4.PubMedCrossRef

43.

Glaser M, Arstad E. “Click labeling” with 2-[18f]fluoroethylazide for positron emission tomography. Bioconjug Chem 2007;18:989–93.PubMedCrossRef

44.

Leyton J, Iddon L, Perumal M, Indrevoll B, Glaser M, Robins E, et al. Targeting somatostatin receptors: preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET. J Nucl Med 2011;52:1441–8.PubMedCrossRef

45.

Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, et al. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med 2010;51:454–61.PubMedCrossRef

46.

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.PubMedCrossRef

47.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRef

48.

Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 2011;52:841–4.PubMedCrossRef

49.

Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228–47.PubMedCrossRef

50.

Nicolas G, Giovacchini G, Müller-Brand J, Forrer F. Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin North Am 2011;40:187–204.PubMedCrossRef

51.

Hubalewska-Dydejczyk A, Fröss-Baron K, Mikolajczak R, Maecke HR, Huszno B, Pach D, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur J Nucl Med Mol Imaging 2006;33:1123–33.PubMedCrossRef

52.

Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 2009;42:832–41.PubMedCrossRef

53.

Ginj M, Schmitt JS, Chen J, Waser B, Reubi JC, de Jong M, et al. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol 2006;13:1081–90.PubMedCrossRef

54.

Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005;11:1136–45.PubMed

55.

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982–93.PubMedCrossRef

56.

Fani M, Mueller A, Tamma ML, Nicolas G, Rink HR, Cescato R, et al. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. J Nucl Med 2010;51:1771–9.PubMedCrossRef

57.

Reubi JC, Eisenwiener KP, Rink H, Waser B, Mäcke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002;456:45–9.PubMedCrossRef

58.

Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H, et al. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin Cancer Res 2008;14:2019–27.PubMedCrossRef

59.

Cescato R, Loesch KA, Waser B, Mäcke HR, Rivier JE, Reubi JC, et al. Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol 2010;24:240–9.PubMedCrossRef

60.

Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006;103:16436–41.PubMedCrossRef

61.

Cescato R, Erchegyi J, Waser B, Piccand V, Maecke HR, Rivier JE, et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem 2008;51:4030–7.PubMedCrossRef

62.

Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 2011;52:1412–7.PubMedCrossRef

63.

Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000;27:1694–9.PubMedCrossRef

64.

Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008;49:318–26.PubMedCrossRef

65.

Smith CJ, Gali H, Sieckman GL, Higginbotham C, Volkert WA, Hoffman TJ. Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7–14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem 2003;14:93–102.PubMedCrossRef

66.

Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 2008;35:401–11.PubMedCrossRef

67.

García Garayoa E, Rüegg D, Bläuenstein P, Zwimpfer M, Khan IU, Maes V, et al. Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. Nucl Med Biol 2007;34:17–28.PubMedCrossRef

68.

García Garayoa E, Schweinsberg C, Maes V, Rüegg D, Blanc A, Bläuenstein P, et al. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors. Q J Nucl Med Mol Imaging 2007;51:42–50.PubMed

69.

Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwé DA, Schubiger PA, et al. Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug Chem 2008;19:2432–9.PubMedCrossRef

70.

García Garayoa E, Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwe DA, et al. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. Bioconjug Chem 2008;19:2409–16.PubMedCrossRef

71.

Garrison JC, Rold TL, Sieckman GL, Naz F, Sublett SV, Figueroa SD, et al. Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7–14)NH2 structural paradigm in a prostate cancer model. Bioconjug Chem 2008;19:1803–12.PubMedCrossRef

72.

Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 2007;48:1327–37.PubMedCrossRef

73.

Pradhan TK, Katsuno T, Taylor JE, Kim SH, Ryan RR, Mantey SA, et al. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol 1998;343:275–87.PubMedCrossRef

74.

Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004;64:6707–15.PubMedCrossRef

75.

Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, et al. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6–14) analog. J Nucl Med 2005;46:691–9.PubMed

76.

Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, Schmieder K, Eisenhut M, Haberkorn U, et al. Pharmacokinetic studies of 68Ga-labeled bombesin (68Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results. Clin Nucl Med 2011;36:101–8.PubMedCrossRef

77.

Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, et al. 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006;47:1144–52.PubMed

78.

Waser B, Eltschinger V, Linder K, Nunn A, Reubi JC. Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA. Eur J Nucl Med Mol Imaging 2007;34:95–100.PubMedCrossRef

79.

Bodei L, Ferrari M, Nunn A, Lull JB, Cremonesi M, Martano L, et al. 177Lu-AMBA Bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations. Eur J Nucl Med Mol Imaging 2007;34 Suppl 2:S221.

80.

Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1198–208.PubMedCrossRef

81.

Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, et al. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res 2011;71:1009–18.PubMedCrossRef

82.

Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009;15:5240–9.PubMedCrossRef

83.

Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011;38:97–107.PubMedCrossRef

84.

Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin releasing peptide receptor positive tumors. J Nucl Med 2011. doi:10.2967/jnumed.111.094375.

85.

Gornik G, Mansi R, Maecke H, Weber WA, et al. Evaluation of the GRPR radioantagonist 64Cu-CB-TE2A-AR-06 in mice and men. J Nucl Med 2011;52 Suppl 1:7P.

86.

Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, et al. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med 2011;52:270–8.PubMedCrossRef

87.

Behr TM, Béhé MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32:97–109.PubMedCrossRef

88.

Wank SA. G protein-coupled receptors in gastrointestinal physiology. I. CCK receptors: an exemplary family. Am J Physiol 1998;274:G607–13.PubMed

89.

Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998;25:481–90.PubMedCrossRef

90.

Roosenburg S, Laverman P, Joosten L, Eek A, Oyen WJ, de Jong M, et al. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation. Bioconjug Chem 2010;21:663–70.PubMedCrossRef

91.

Laverman P, Béhé M, Oyen WJ, Willems PH, Corstens FH, Behr TM, et al. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem 2004;15:561–8.PubMedCrossRef

92.

Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, et al. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 1999;5:3124s–38s.PubMed

93.

Béhé M, Becker W, Gotthardt M, Angerstein C, Behr TM. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 2003;30:1140–6.PubMedCrossRef

94.

Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012–5.PubMed

95.

Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 2008;35:1868–77.PubMedCrossRef

96.

Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 2007;48:615–22.PubMedCrossRef

97.

Nock BA, Maina T, Béhé M, Nikolopoulou A, Gotthardt M, Schmitt JS, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 2005;46:1727–36.PubMed

98.

Fröberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:1265–72.PubMedCrossRef

99.

von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1209–18.CrossRef

100.

von Guggenberg E, Sallegger W, Helbok A, Ocak M, King R, Mather SJ, et al. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. J Med Chem 2009;52:4786–93.CrossRef

101.

Sosabowski JK, Matzow T, Foster JM, Finucane C, Ellison D, Watson SA, et al. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med 2009;50:2082–9.PubMedCrossRef

102.

Kolenc-Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem 2011;54:2602–9.PubMedCrossRef

103.

Aloj L, Aurilio M, Rinaldi V, D’ambrosio L, Tesauro D, Peitl PK, et al. Comparison of the binding and internalization properties of 12 DOTA-coupled and (111)In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging 2011;38:1417–25.PubMedCrossRef

104.

Ocak M, Helbok A, Rangger C, Peitl PK, Nock BA, Morelli G, et al. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging 2011;38:1426–35.PubMedCrossRef

105.

Laverman P, Joosten L, Eek A, Roosenburg S, Peitl PK, Maina T, et al. Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging 2011;38:1410–6.PubMedCrossRef

106.

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781–93.PubMedCrossRef

107.

Singh G, Eng J, Raufman JP. Use of 125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig. Regul Pept 1994;53:47–59.PubMedCrossRef

108.

Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, et al. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006;47:2025–33.PubMed

109.

Gotthardt M, Lalyko G, van Eerd-Vismale J, Keil B, Schurrat T, Hower M, et al. A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept 2006;137:162–7.PubMedCrossRef

110.

Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007;13:3696–705.PubMedCrossRef

111.

Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008;359:766–8.PubMedCrossRef

112.

Christ E, Wild D, Forrer F, Brändle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009;94:4398–405.PubMedCrossRef

113.

Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brändle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011;52:1073–8.PubMedCrossRef

114.

Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010;37:1345–55.PubMedCrossRef

115.

Hubalewska-Dydejczyk A, Sowa-Staszczak A, Mikolajczak R, Pach D, Janota B, Tomaszuk M, et al. 99mTc labeled GLP-1 scintigraphy with the use of [Lys40-(Ahx-HYNIC/EDDA)NH2]-Exendin-4 in the insulinoma localization. J Nucl Med 2011;52 Suppl 1:561.

116.

Sowa-Staszczak A, Stefanska A, Pach D, Tomaszuk M, Jabrocka-Hybel A, Glowa B, et al. First clinical application of 99mTc labelled long-acting agonist of GLP-1 (Exendin-4) in endocrine diagnosis. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 2:S206.

117.

Brom M, Baumeister P, Melis M, Laverman P, Joosten L, Behe M, et al. Determination of the beta-cell mass by SPECT imaging with In-111-DTPA-Exendin-3 in rats. J Nucl Med 2009;50 Suppl 2:147.

118.

Connolly BM, Vanko A, McQuade P, Guenther I, Meng X, Rubins D, et al. Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist. Mol Imaging Biol 2011. doi:10.1007/s11307-011-0481-7.

119.

Wu Z, Todorov I, Li L, Bading JR, Li Z, Nair I, et al. In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor. Bioconjug Chem 2011;22:1587–94.PubMedCrossRef

120.

Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med 2010;363:1289–90.PubMedCrossRef

121.

Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9–22.PubMedCrossRef

122.

Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging 2010;37 Suppl 1:S86–S103.PubMedCrossRef

123.

Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2:e70.PubMedCrossRef

124.

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006;12:3942–9.PubMedCrossRef

125.

Indrevoll B, Kindberg GM, Solbakken M, Bjurgert E, Johansen JH, Karlsen H, et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett 2006;16:6190–3.PubMedCrossRef

126.

Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, et al. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008;49:879–86.PubMedCrossRef

127.

Cho HJ, Lee JD, Park JY, Yun M, Kang WJ, Walsh JC, et al. First in human evaluation of a newly developed PET tracer, 18F-RGD-K5 in patients with breast cancer: comparison with 18F-FDG uptake pattern and microvessel density. J Nucl Med 2009;50 Suppl 2:1910.

128.

Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 2004;15:41–9.PubMedCrossRef

129.

Decristoforo C, Hernandez Gonzalez I, Carlsen J, Rupprich M, Huisman M, Virgolini I, et al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2008;35:1507–15.PubMedCrossRef

130.

Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ, et al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008;49:830–6.PubMedCrossRef

131.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med 2004;45:1776–83.PubMed

132.

Chen X, Park R, Hou Y, Khankaldyyan V, Gonzales-Gomez I, Tohme M, et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004;31:1081–9.PubMedCrossRef

133.

Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS. Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 2004;3:96–104.PubMedCrossRef

134.

Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, et al. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med 2006;47:113–21.PubMed

135.

Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146–51.PubMed

136.

Dijkgraaf I, Yim CB, Franssen GM, Schuit RC, Luurtsema G, Liu S, et al. PET imaging of alphavbeta3 integrin expression in tumours with 68Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 2011;38:128–37.PubMedCrossRef

137.

Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007;48:1162–71.PubMedCrossRef

138.

Liu Z, Niu G, Shi J, Liu S, Wang F, Chen X. (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging 2009;36:947–57.PubMedCrossRef

139.

Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 2006;47:1434–9.PubMed

140.

Liu S, Liu Z, Chen K, Yan Y, Watzlowik P, Wester HJ, et al. 18F-labeled galacto and PEGylated RGD dimers for PET imaging of alphavbeta3 integrin expression. Mol Imaging Biol 2010;12:530–8.PubMedCrossRef

Titel: Radiopharmaceutical development of radiolabelled peptides
verfasst von: Melpomeni Fani
Helmut R. Maecke
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe Sonderheft 1/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-2001-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2012

Radiolabelled peptides in diagnosis and therapy: an introduction

Radiolabelled RGD peptides for imaging and therapy

Rationale for the use of radiolabelled peptides in diagnosis and therapy

Gallium-labelled peptides for imaging of inflammation

111In-DTPA0-octreotide (Octreoscan), 131I-MIBG and other agents for radionuclide therapy of NETs

68Ga-labelled peptides in the management of neuroectodermal tumours